Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults. It is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis; and other product candidates in various stages of clinical and preclinical development. The company has a license agreement with Aralez Pharmaceuticals Canada Inc. to develop and commercialize bezafibrate in the United States. It markets its products through an internal commercial organization and third-party distributors. The company was incorporated in 2002 and is headquartered in New York, New York.
Intercept Pharmaceuticals Stock Up 9.5 %
Shares of NASDAQ:ICPT traded up $1.53 during trading on Friday, reaching $17.60. 1,685,401 shares of the company traded hands, compared to its average volume of 849,542. The firm has a fifty day simple moving average of $14.08 and a 200 day simple moving average of $15.56. The firm has a market cap of $524.48 million, a P/E ratio of -8.11 and a beta of 1.24. Intercept Pharmaceuticals has a 1-year low of $10.81 and a 1-year high of $20.50.
Intercept Pharmaceuticals (NASDAQ:ICPT - Get Rating) last issued its earnings results on Wednesday, August 3rd. The biopharmaceutical company reported ($0.68) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.53) by ($0.15). The business had revenue of $100.40 million for the quarter, compared to the consensus estimate of $94.85 million. As a group, research analysts anticipate that Intercept Pharmaceuticals will post -2.92 EPS for the current year.
Analyst Ratings Changes
A number of research analysts recently commented on the stock. Cowen lowered their price objective on shares of Intercept Pharmaceuticals to $22.00 in a research note on Tuesday. Raymond James lifted their price target on shares of Intercept Pharmaceuticals from $23.00 to $26.00 and gave the stock an "outperform" rating in a research report on Thursday, August 4th. SVB Leerink decreased their price target on shares of Intercept Pharmaceuticals from $27.00 to $21.00 and set a "market perform" rating on the stock in a research report on Friday, July 8th. StockNews.com lowered shares of Intercept Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Thursday, August 4th. Finally, HC Wainwright decreased their price objective on shares of Intercept Pharmaceuticals from $18.00 to $16.00 and set a "neutral" rating for the company in a research note on Monday, August 8th. One investment analyst has rated the stock with a sell rating, seven have given a hold rating and three have assigned a buy rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Hold" and a consensus price target of $21.36.